biostudies-literatureUnknown64(12)Watabe TGlypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with ⁸⁹Zr or ²¹¹At as a theranostic target in pancreatic ductal adenocarcinoma. <b>Methods:</b> GPC1 mAb clone 01a033 was labeled with ⁸⁹Zr or ²¹¹At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (<i>n</i> = 6) were intravenously administered [⁸⁹Zr]GPC1 mAb (0.91 ± 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each <i>n</i> = 3) and a blocking study. DNA double-strand breaks were evaluated using the γH2AX antibody. The antitumor effect was evaluated by administering [²¹¹At]GPC1 mAb (∼100 kBq) to PANC-1 xenograft mice (<i>n</i> = 10). <b>Results:</b> GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [⁸⁹Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUV_max, 3.85 ± 0.10), which gradually decreased until day 7 (SUV_max, 2.16 ± 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUV_max, 4.66 ± 0.40 and 2.36 ± 0.36, respectively; <i>P</i> = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 ± 1.3 and 12.4 ± 3.0, respectively; <i>P</i> = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [²¹¹At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [²¹¹At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [²¹¹At]GPC1 mAb, suggesting an essential role in targeted α-therapy. <b>Conclusion:</b> [⁸⁹Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [²¹¹At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.Journal of nuclear medicine : official publication, Society of Nuclear Medicine1949-1955https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690121biostudies-literatureImmuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with ⁸⁹Zr or ²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.PMC10690121Haba HShimosegawa EToyoshima AKobayashi TFukase KYamamoto RKaneda KSerada STomiyama NWatabe TKurimoto KKabayama KWang YOoe KNaka SNaka TfalseImmuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with ⁸⁹Zr or ²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with ⁸⁹Zr or ²¹¹At as a theranostic target in pancreatic ductal adenocarcinoma. <b>Methods:</b> GPC1 mAb clone 01a033 was labeled with ⁸⁹Zr or ²¹¹At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (<i>n</i> = 6) were intravenously administered [⁸⁹Zr]GPC1 mAb (0.91 ± 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each <i>n</i> = 3) and a blocking study. DNA double-strand breaks were evaluated using the γH2AX antibody. The antitumor effect was evaluated by administering [²¹¹At]GPC1 mAb (∼100 kBq) to PANC-1 xenograft mice (<i>n</i> = 10). <b>Results:</b> GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [⁸⁹Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUV_max, 3.85 ± 0.10), which gradually decreased until day 7 (SUV_max, 2.16 ± 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUV_max, 4.66 ± 0.40 and 2.36 ± 0.36, respectively; <i>P</i> = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 ± 1.3 and 12.4 ± 3.0, respectively; <i>P</i> = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [²¹¹At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [²¹¹At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [²¹¹At]GPC1 mAb, suggesting an essential role in targeted α-therapy. <b>Conclusion:</b> [⁸⁹Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [²¹¹At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.2023-01-01T00:00:00Z2023 Dec2025-04-25T17:33:22.57Z2025-04-06T04:05:20.996ZS-EPMC106901213782784110.2967/jnumed.123.266313